Society Task-force, made up ofa panel ofexperts working in 2007-2008. The aim is to give clear indications on the use of the drugs most employed in children, grading the quality of evidence and the strength of recommendations. Suggestions on their limits due to unlicensed and off-label use are reported. The level of evidence and the strength of recommendations for different therapeutic approaches demonstrate that frequently the use of drugs in children is extrapolated from the experience in adults and that more studies are required to endorse the correct use of different drugs in asthmatic children.
METHODS
From 2007 until the end of 2008, the Task Force was constituted of a panel of experts, members of the Italian Paediatric Society, who evaluated articles from The Cochrane Register of Controlled Trials (CENTRAL), PubMed, EMBASE, the lists of references in relevant publications, and the authors' collection ofreferences. Information regarding drugs mentioned in the paper are available on the website: http://emc.medicines.org.uk; however, license regulations may vary among countries and readers are invited to consult their national regulations.
Evidence levels were graded as proposed by the BMJClinicalEvidenceGradingofRecommendations, Assessment, Development and Evaluation (GRADE) working group (1) . The GRADE score system takes into account the type of evidence, the quality, the consistency, the directness and the size of the effect; evidence was classified as low, fair, moderate, high or expert opinion; benefits were described as none, conflicting, small/weak, intermediate or substantial; strength of recommendation was classified as strong or weak (Table I) (1) .
Acute asthma is defined as an acute exacerbation of wheezing, unresponsive to usually effective therapy and necessitating care in an emergency room or hospital ward. An acute asthma attack is characterized by airway narrowing and inflammation, hyperinflation, impairment of pulmonary function, alterations in alveolar ventilation and hypoxemia.
Attacks ofwheezing induced by upper respiratory viral infections are common in pre-school children and can be confused with acute asthma exacerbations, but they have different treatment strategies.
CLINICAL EVALUATION
Quick and careful clinical evaluation of the child, made to assess the severity of acute asthma, is essential to develop a therapeutic plan. Anamnestic and clinical parameters are fundamental to evaluate the patient, even if they have little correlation to the severity of each asthma episode (Table II) , therefore it is necessary to monitor: 02 Saturation (Sa02) (%), Peak Expiratory Flow (PEF) or Forced Expiratory Volume at 1 second (FEV1) and in severe cases Partial Arterial C02 Pressure (Pa C02) (4) (5) (6) .
In children who are not able to perform spirometric monitoring, a close clinical monitoring should be effectuated to establish the severity of asthma. Not all parameters of severity score need to be fulfilled to classify asthma severity.
Mild asthma exacerbations, according to the suggestions of a recent ATS/ERS task force was not taken into consideration in this paper, because symptoms or changes in flow rates may reflect transient loss of asthma control rather than the early stages of severe exacerbation. (7) Recommendation 1. In children with acute asthma exacerbation Sa02, PEF or FEV 1 and, in severe cases, Pa C02 should be evaluated to establish the grade of severity. Level of evidence high; benefits were substantial; strength of recommendation strong (1B). Great attention must be paid to factors associated with severe asthma exacerbations such as previous admission to PICU, two or more admissions or visits in ED in the last year, usual and/or recurrent use of systemic corticosteroids, increased need for bronchodilator therapy during the last weeks or months, low social economic conditions, etc.
TREATMENT

Oxygen therapy
The administration of oxygen should be regulated by pulse oximetry; children with Sa02 <92% should receive humidified oxygen by facemask, or nasal cannula with sufficient flow to achieve and maintain a normal oxygen saturation (::: 95%) (4, (8) (9) . In a review (9) of several randomised clinical studies (RCS), in which a placebo replaced oxygen therapy, it was demonstrated that progressive hypoxemia is probably an important cause of death, and oxygen should be the first treatment given to any patient with acute severe asthma.
Recommendation
All children with an acute asthma exacerbation
should receive humidified oxygen to achieve or maintain normal oxygen saturation. Level of evidence expert opinion: benefits were substantial; strength of recommendation: strong (60).
Drugs
Drugs normally used in acute asthma and the corresponding doses are reported in Table III .
Beta, agonists
The short-acting beta2 agonists represent the first choice treatment in acute asthma exacerbation for their bronchodilator effect.
Continuous inhaled beta-agonist treatment (CBA) does not offer advantages compared to intermittent treatment. (11) (12) As regards the side effects, intermittent inhaled beta-agonists, compared to CBA, increased the heart rate from baseline (30 beats/min vs 18 beats/min), but tremor was equally common in both treatment groups (RR= 0.56, IC 95% from 0.21 to 1.40) (11) .
The administration of beta 2 agonist using an MDI with spacer is an effective alternative to nebulizers for the treatment of children with severe or potentially severe acute asthma in the emergency department (13) . The dose of beta2 agonists administered by MDI with spacer must be guided by the severity of the acute asthma exacerbation as reported in Table III. When there is a scarce response to inhaled beta2 agonist, salbutamol may be administered intravenously, under close clinical monitoring, in children admitted to the ED (14) .
• Current unlicensed and off-label use
Salbutamol standard pMDIs and inhalation solution are indicated for the relief of bronchospasm in children over 2 years of age; although salbutamol is widely used in children under 2 years of age.
Recommendation 3. Nebulised salbutamol should be administered every 20-30 minutes and at high cumulative doses in severe acute asthma exacerbation. Level of evidence: high; benefit: substantial; strength of recommendation: strong (IA) 4. Continuous inhaled beta-agonist treatment does not offer advantages compared to intermittent treatment. Level of evidence: moderate; benefit: substantial; strength of recommendation: strong.
5.
In moderate acute asthma exacerbation the MDI with spacer is the optimal device for providing beta2 agonists. Level of evidence: high; benefit: substantial; strength of recommendation: strong (IA). 6. The dose ofbeta2 agonists administered by MDI with spacer must be guided by the severity of the acute asthma exacerbation, at least 2-4 sprays (200-400 meg), every 20-30', with variable frequency, depending on the clinical response. Level of evidence: high; benefit: substantial; strength of recommendation: strong (1B) 7. Salbutamol (administered intravenously) is recommended as an alternative to conventional therapy in unresponsive cases of life-threatening asthma. Level of evidence: moderate-high; benefit: substantial; strength of recommendation: strong (2B)
Anticholinergic drugs
Anticholinergic drugs are slowerbronchodilatators than beta2 agonists; nevertheless, they are synergic. Ipratropium bromide is commonly used in children.
Ipratropium bromide
For children over 2 years of age, and in cases of moderate and severe asthma exacerbation, the addition of inhaled ipratropium bromide in multiple doses to beta2 agonists should be considered (15) . A short cut review of 148 papers, carried out to establish whether adding inhaled anti-cholinergics to betaagonists improves outcome in the treatment of acute childhood asthma, concluded that anti-cholinergics reduce time to recovery and discharge, and may reduce admissions for moderate to severe asthmatic children (14) . In children under 2 years, ipratropium bromide added to beta2 agonists is less effective (17) . Dosage for children are reported in Table III .
• Current unlicensed and off-label use
Aerocaps of ipratropium bromide are not recommended for asthmatic children under 12 years of age. A CFC-free inhaler is suggested in asthmatic children 6 to 12 years of age or in children under 6 (a lower age limit is not specified).
Recommendation 8. For children over 2 years of age, in cases of moderate and severe asthma exacerbation inhaled ipratropium bromide should be added to beta2 agonists. Level of evidence: high; benefit: substantial; strength of recommendation: strong (lA).
Corticosteroids (CS)
The early use of systemic corticosteroids (SCS) in acute asthma exacerbation may reduce the frequency of hospitalizations and prevent a relapse of symptoms after initial administration.
SCS must be administered early in the treatment of moderate and severe acute asthma exacerbation. The SCS need at least 2-4 hours to determine a significant clinical improvement. There are no significant differences between the methods of administration (oral or IV), although oral administration is preferred because is less invasive and less expensive (18) (19) . The dosage of oral corticosteroids is reported in Table III . Lower doses of steroids may be equally effective in children, with fewer side effects (20) . Experts recommend 3-5 days of therapy, excluding the need to taper the SCS at the end of the therapy (21) .
The scientific evidence is currently insufficient to recommend the use of high dose inhaled corticosteroids (ICS) as an alternative or in addition to oral steroids in acute asthma exacerbation. (22) In a recent meta-analysis (23), Rodrigo et al. evaluated the effectiveness of ICS in the first 4 hours from the beginning of treatment in adults and children (4 SCR, 285 patients) with acute severe asthma. Patients subjected to ICS showed a more rapid clinical improvement than those subjected to placebo or to SCS, with a 40% reduction of the risk of being admitted in the ED in the first 4 hours.
• Current unlicensed and off-label use
None when used in asthma Recommendation 9. CSs (oral or IV) should be administered early in the treatment of moderate and severe asthma exacerbations, with clinical improvement usually not before 4 hours after administration. Level of evidence: high; benefit: substantial; strength of recommendation: strong (lA). 10 . The use of ICS as an alternative or in addition to oral steroids in acute asthma exacerbation. ICS is not recommended. Level of evidence: moderate; benefit: intermediate; strength of recommendation: strong (3C).
Aminophylline
The association of aminophylline IV to beta2 agonist and of aminophylline IV to beta2 agonist and SCS in severe asthma exacerbation does not offer significant advantages and it can even cause serious side effects; nevertheless some patients benefit from this drug. (24) • Current unlicensed and off-label use
The use of aminophylline IV in children under 6 months of age is generally not recommended. 
Epinephrine
Inhaled epinephrine does not show any additional benefit compared with beta-2 agonist in the treatment of acute asthma exacerbation and can cause side effects, especially in hypoxemic patients (25) . Dosage for children is reported in Table III .
• Current unlicensed and off-label use
None when used in asthma Recommendation 12. Epinephrine (administered subcutaneously or intravenously) is not recommended in acute asthma exacerbations, it can be used as an alternative after LV. beta-2-agostinst therapy in unresponsive cases of life-threatening asthma. Level of evidence: weak; benefit: little; strength of recommendation: strong (40).
Leukotriene Receptor Antagonists (LRAs)
The effect of LRAs in acute asthma exacerbation is, however, not confirmed and leukotriene antagonists are not yet established as agents for acute management in moderate-severe asthma exacerbations in ED. (26) Recommendation 13. The use of montelukast is not recommended in children with acute asthma exacerbation. Level of evidence: weak; benefit: little; strength of recommendation: strong.
Magnesium sulfate
Experiences in children are limited and relate to a single IV dose, 25-75 mg / kg in 20' (27) ; data on safety and efficacy of using repeated doses is not currently available.
Recent reports indicate the use of isotonic solution of MgS04 with nebulizer in addition to bronchodilator in severe asthma; it improves lung function, but not the percentage of hospitalizations (28) .
• Current unlicensed and oif-Iabel use
This drug is not licensed for acute asthma exacerbations.
Recommendation 14. IV Magnesium sulfate (MgS04) is not recommended in children with severe asthma exacerbation. It use can be considered in a single dose in non-responsive children and/or with FEV 1 less than 60% after one hour of therapy. Level of evidence: high, benefit: little, strength of recommendation: strong (lB).
Heliox
Helium is a low density gas; therefore the inhalation of a mixture containing helium/oxygen (Heliox) can reduce respiratory fatigue and improve ventilation in patients with obstruction of airways. A helium-oxygen mixture (70%/30%) can be used as a carrier for administration of inhaled bronchodilators in patients with life threatening asthma, after one hour of conventional therapy.
This gas can be used, as an alternative to oxygen, in severe asthma exacerbation that does not respond to initial treatment. (29) Recommendation 15. The use of Heliox as an alternative to oxygen therapy is not recommended in acute asthma. Level of evidence: moderate; benefit: little; strength of recommendation: strong (3C).
DEVICES FOR INHALATION IN ACUTE ASTHMA EXACERBATION
Nebulizers, dry powder inhalers (DPI) and MOl are the devices used for inhalation in acute asthma exacerbations. Use of MDIs with spacers, with! without facemasks, is recommended for paediatric patients. For the effective use ofMDIs with spacers, it is crucial that the doctor chooses the device that is best suited to each patient and that the patient is trained on its correct use (30) .
Recommendation
Use of MDIs with spacers, with!without
facemasks, is recommended for paediatric patients with acute asthma exacerbation. Level of evidence: moderate, benefit: substantial, strength of recommendation: strong
Hydro-electrolytic balance Some children during acute asthma exacerbations have variable dehydration and can require adequate hydration. Intravenous is preferred if the patient vomits, or during severe respiratory distress. An excessive intake of fluid must be avoided to prevent pulmonary oedema. (31) Salbutamol infusions, aminophylline and steroids can cause a decrease in blood potassium concentrations, with possible side effects on muscle contraction and cardiac rhythm; IV potassium should be administered, according to the results of regular blood controls. (32)
Recommendation
In all patients with acute asthma exacerbations
in the ED dehydration should be prevented, especially if IV therapy for severe asthma is necessary. Level of evidence expert opinion benefit: substantial; strength ofrecommendation: strong (60) o Good practice points: recommended best practice based on the clinical experience of the guideline development group.
Endotracheal intubation and invasive ventilation
Endotracheal intubation should be carried out on patients who, despite correct medical therapy and 02 administration, present:
-a progressive increase of PaC02 -an exhaustion of respiratory muscle contraction -persistent hypoxia -alteration of conscience. The choice of endotracheal intubation is not based on simple evaluation of numerical parameters, but on the clinical judgement of an expert team.
Except for respiratory arrest, there are no absolute criteria for these procedures. The decision ofcarrying out intubation on a patient cannot be simply based on the evaluation of numerical parameters, but on the clinical judgement of an expert team, including an anaesthesiologist (33) .
Recommendation
18. In cases of severe asthma exacerbation endotracheal intubation and invasive ventilation should be considered. Level of evidence expert opinion, benefit: substantial, strength of recommendation: strong (60).
OPERATIVE DECISIONS
The level of treatment of an acute asthma exacerbation depends on its severity and on the response to therapy. The management of acute asthma exacerbations starts at home. Most patients show a gradual improvement after conventional therapy. A minority of them may present a progressive clinical deterioration (34) and, if a more aggressive treatment is ineffective, they should be 
INDICATIONS FOR HOSPITALIZATION
Panel members do not agree on predictive criteria of evolution of an acute asthmatic episode. For this reason, it is recommended that the decision of hospitalization should be made after the evaluation of anamnestic, clinical and functional parameters and after a continuous monitoring of the patient. Absolute indications for hospitalization are: signs and symptoms ofacute respiratory failure, worsening ofclinical parameters after bronchodilator treatment, Sat02<92% after bronchodilator treatment, concomitant complications (pneumothorax, atelectasies, etc.) (Table IV) . When the patient leaves hospital, the symptoms must be minimal, PEF >75%; it is necessary to check the child's ability to correctly operate the inhaler, to continue treatment with beta2 agonists for at least a week, to consider the use of ICS, to deliver written information on the treatment of acute exacerbations, and to plan a control visit with general practitioner within a week and in a 
CONCLUSIONS
This update on acute asthma exacerbations in children is based on evidence statements and grades of recommendations.
Although several asthma guidelines providing helpful information are available, this paper aims to underline some aspects of asthma management in children: for example the association of ipratropium bromide and beta2 agonists in acute asthma and the possible use of magnesium sulphate. Another topic is the current use of unlicensed and off-label drugs, which is frequent in children and potentially harmful. Their use varies from country to country, depending on local laws and regulations. This last aspect may be a potential starting point for clinical research in order to improve the treatment of children with acute asthma exacerbations.
The best strategy, in case of acute asthma exacerbation, is to start treatment at home with a rapid pharmacologic intervention to prevent the worsening of symptoms and to reduce emergency visits and hospitalizations. When symptoms progressively deteriorate despite pharmacological treatment, it is mandatory to send the patient to ED. Close cooperation between the paediatrician, general practitioner, ED staff, nursing staff and, wherever possible, the child and his family is essential for the appropriate management of this kind of emergency. Diagnostic and therapeutic algorithms simplify the clinical management of acute asthma and they are a useful educational tool for every professional caregiver involved.
